Canadian Cancer Supportive Care Drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Cancer is the leading cause of death in Canada. Over 25% of all cancer deaths in Canada are due to lung cancer. The burden of cancer in Canada continues to rise. In 2017, over 200,000 Canadians were diagnosed with cancer, and 80,000 died from cancer. Nearly 1 in 2 Canadians will be diagnosed with cancer during their lifetime, and 1 in 4 will die from the disease. Cancer supportive care drugs are used to aid the treatment and reduce the side effects of cancer drugs and medicine. Due to the high prevalence of the disease, the growing demand for various cancer therapies is expected to drive the Canadian cancer supportive care market growth during the forecast period.



Market Drivers

With the increasing prevalence of cancer, several organizations and governments are taking the initiations to manufacture cancer-supportive care products to meet the growing need to treat cancer. Presently, various products are going through clinical trials that can be utilized to treat several side effects of cancer therapy, which is expected to propel the growth of the supportive cancer care products market. Increasing development has led to significant progress in cancer research and therapy in the biopharmaceutical sector. Drug discovery developments have led to lower death rates among patients who have cancer. Improvements were made in cancer pain management. However, because of bad evaluation by doctors and the absence of proper understanding of new medicines and therapy, these improvements have been underutilized.